Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Targeting paraptosis in cancer: opportunities and challenges

Exploring paraptosis as a therapeutic approach in cancer treatment

Paraptosis: a non-classical paradigm of cell death for cancer therapy

Parthanatos And Its Associated Components: Promising Therapeutic Targets For Cancer

Small-molecule Compounds Target Paraptosis to Improve Cancer Therapy

Paraptosis—A Distinct Pathway to Cell Death

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine

Targeting Regulated Cell Death with Pharmacological Small Molecules: an Update on Autophagy-Dependent Cell Death, Ferroptosis, and Necroptosis in Cancer

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Targeting Programmed Cell Death Using Small-Molecule Compounds To Improve Potential Cancer Therapy

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Regulated Cell Death in Cancer: from Pathogenesis to Treatment

Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

Targeting Apoptotic and Autophagic Pathways for Cancer Therapeutics

Targeting Apoptotic Pathway of Cancer Cells with Phytochemicals and Plant-Based Nanomaterials

Caspase-Mediated Programmed Cell Death Pathways As Potential Therapeutic Targets in Cancer

Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells.

Cell death pathologies: targeting death pathways and the immune system for cancer therapy